导读： CRISPR-TO技术实现了对内源RNA空间定位的精准调控，为研究RNA功能及相关疾病提供了新工具。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近 日 ， 美 国 斯 坦 福 大 学 的 亓 磊 实 验 室 在 Nature 杂 志 在 线 发 表 了 题 为 "Programmable control of spatial transcriptome in l i ve cel l s and neurons" 的 研 究 论 文 ， 开 发 了 一 种 新 型 的 可 编 程 方 法 来 调 控 内 源 RNA 的 空 间 定 位 ， 该 方 法 称 为 CRISPR 介 导 的 空 间 转 录 组 调 控 技 术 （CRISPR-mediated transcriptome organi zation, CRISPR-TO）。该项研究为系统性地研究内源RNA定位在多种生物学体系中的功 能提供了全新的工具。 CRISPR-TO利用I I类VI型CRISPR-Cas13系统进行空间转录组的调控。I I类VI型CRISPR-C ...

Group 1 - The core viewpoint of the article is the introduction of the Magnetic Array Humanized Mouse Immune Antibody Discovery Platform (MIT-humAb) by Sanyou Bio, which enhances the existing antibody libraries and aims to produce high-affinity human antibodies efficiently [1][2][3] - The platform integrates various technologies, including humanized mouse immunization, phage display antibody library construction, and high-throughput screening, to generate a diverse range of lead antibody molecules [1][2][4] - Sanyou Bio has established itself as a pioneer in the commercialization of mouse immune libraries, having built 2,798 MIT immune libraries with a cumulative capacity of 720 billion by March 2025, and has successfully supported over 811 projects [3] Group 2 - The platform features high immunogenicity, allowing for the generation of high-affinity antibodies comparable to non-humanized mice, as evidenced by ELISA results showing an immunogenicity of 360,000 for both types of mice [4][6] - It employs a diverse range of screening techniques, ensuring that each target can yield dozens to hundreds of lead antibody molecules through various selection strategies [6][8] - The platform boasts high-throughput screening capabilities, significantly reducing the screening cycle to just 21 days while enhancing overall efficiency and throughput for drug development [8][9] Group 3 - A representative case involves Target A, an immune checkpoint protein that plays a crucial role in cancer immunotherapy, with existing inhibitors developed by multiple companies for various cancers [9][10] - The antibody discovery process for Target A utilized the MIT-humAb platform, successfully identifying candidate antibodies with specific binding capabilities, validated through ELISA testing [10][12] - The platform is expected to play an increasingly important role in generating high-affinity, high-specificity antibodies for various disease targets, particularly in cancer immunotherapy and autoimmune disease research [14] Group 4 - Sanyou Bio is a high-tech biopharmaceutical company headquartered in Shanghai, China, with a vision to improve human life quality through innovative biopharmaceuticals and a mission to facilitate the development of innovative biopharmaceuticals [15] - The company has established a comprehensive research and development platform, focusing on new drug discovery, preclinical research, and intelligent drug development, with over 20,000 square meters of R&D and GMP facilities [15] - Sanyou Bio has built a global marketing network, collaborating with over 1,200 pharmaceutical and biotech companies, and has completed more than 1,200 new drug discovery and development service projects [15]